Enrollees Sought for Trial of Vaccine for C. diff – UW Medicine | Newsroom
The C diff vaccine trial at UW Medicine is recruiting participants to evaluate a preventive vaccine against Clostridioides difficile infections. This vaccine trial aims to reduce the risk of severe colitis caused by C diff, especially in vulnerable…
Texas Launches State-Sponsored Psychedelic Research with Ibogaine Trials
Texas is pioneering state-sponsored psychedelic research by initiating ibogaine clinical trials for addiction treatment. This approach represents a significant shift in regulatory pathways at the state level. State-sponsored psychedelic research could…
Lawmakers Debate Regulation of Psychedelic Clinical Trials
Legislative frameworks are shaping the regulation of psychedelic clinical trials, impacting patient access to emerging therapies. As FDA approval processes progress for psilocybin and MDMA, lawmakers debate safety and training protocols. Psychedelic…
Cell Therapy Eases Parkinson’s Motor Symptoms in Early Trial
Cell therapy Parkinsons disease trials offer new hope for easing motor symptoms. Early-phase research suggests potential benefits in neurodegeneration treatment. Understanding these advances is crucial for clinicians and patients.
The First Randomized Trial Of Cannabis For Migraine Relief – And What It Found
This randomized controlled trial cannabis migraine study provides preliminary evidence on cannabis for migraine relief. It is the first controlled trial addressing this treatment area. Clinicians now have emerging data to guide migraine patient care.
New Funding to Support SER-252 Trial in Advanced Parkinson’s
The synthetic cannabinoid Parkinsons trial SER-252 targets levodopa-induced dyskinesia in advanced Parkinson's disease. This novel therapeutic approach could improve management of motor symptoms. Ongoing research aims to validate its clinical efficacy…
CBD Shows Promise But Lacks Broad Regulatory Approval: A Sobering Review of the Evidence
The CBD pharmacology regulatory context reveals a narrow evidence base supporting broad approval. Most CBD products lack pharmaceutical-grade quality and regulatory endorsement. This 2024 review highlights the need for rigorous clinical trials and…
Mapping the Clinical Trial Landscape for Cannabinoids in Neurology: A Registry-Based Systematic Review
This systematic review of cannabinoid clinical trials neurological disorders highlights research focused on Multiple Sclerosis, Fibromyalgia, and Parkinson's Disease. It reveals challenges due to inconsistent protocols and dosing across studies. The…
CBD and Anxiety: Promising Signal, Weak Evidence Base
The cbd anxiety clinical trials 2024 review reveals most studies are exploratory with varied designs and small samples. Evidence supporting CBD for anxiety disorders remains weak and inconclusive. This review highlights the urgent need for robust…
Investigational Drugs in PTSD: Emerging Clinical Evidence
The endocannabinoid system and PTSD clinical evidence reveal promising investigational drugs targeting neurobiological pathways. PTSD remains challenging with limited FDA-approved options. Emerging treatments like ketamine and cannabinoids offer hope for…
